The maximal post-exercise fall in FEV1 compared with pre-exercise values at baseline (ie, at randomisation) and after 3 and 6 weeks of treatment in the group inhaling regular placebo and terbutaline on demand, regular budesonide and terbutaline on demand and regular placebo and the combination of budesonide+formoterol on demand
| Baseline | 3 weeks | 6 weeks | |
|---|---|---|---|
| Regular placebo and terbutaline on demand | |||
| Max post-exercise FEV1 fall Relative change (%) | 17.7±8.9 – | 16.9±8.5 −1.6±45.6 | 18.8±10.9 +8.9±55.1 |
| Regular budesonide and terbutaline on demand | |||
| Max post-exercise FEV1 fall Relative change (%) | 15.3±5.7 – | 11.3±7.2 −26.4±7.3 | 9.6±7.0 −38.6±43.4 |
| Regular placebo and budesonide/formoterol on demand | |||
| Max post-exercise FEV1 fall Relative change (%) | 16.4±7.5 – | 12.6±7.2 −18.7±42.3 | 11.1±8.2 −28.5±53.7 |
The exercise test is performed 24 h after the last dose of the study medication. The relative change in EIB following 3 and 6 weeks of treatment indicates the relative change in EIB after treatment compared with pre-exercise EIB. Data are presented as mean±SD.
EIB, exercise-induced bronchoconstriction; FEV1, forced expiratory volume in 1 s.